Milan (Italy) and Nijmegen (The Netherlands) – September 8th 2016 - Axxam, a leading drug discovery company with expertise in early phase discovery biology, and Mercachem, a leading discovery chemistry company with expertise in both medicinal and process chemistry, announce a strategic alliance to provide integrated discovery services spanning all phases from gene to fully optimized leads and beyond. This partnership will allow the companies to offer best-in-class fully integrated drug discovery services, supported by a culture of scientific excellence and innovation.
Axxam and Mercachem Sign a Strategic Alliance for Integrated Drug Discovery Services
Axxam SpA expands to U.S., opens office in Cambridge, Mass.
May 19th, 2016 - Axxam SpA (Milan/Italy), a privately owned innovative Partner Research Organization (iPRO) with a strong and leading expertise for the identification and characterization of bioactive compounds, announced today the opening of its first U.S. office, located in the Cambridge Innovation Center (CIC) in Cambridge, Mass.
Drug Discovery Collaboration between Grünenthal and Axxam
Grünenthal capitalizes on Axxam’s drug discovery platform and expertise to identify small molecule lead structures for its early pipeline in pain and inflammation
Aachen, Germany and Milano, Italy, March 3, 2016: Grünenthal and Axxam announced today that they have entered into an integrated collaboration. The objective is to discover novel small molecule lead structures for the development of pain and inflammation therapeutics by combining Axxam’s drug discovery platform with Grünenthal’s expertise on emerging and innovative biological pathways and targets.
Axxam and the NEOMED Institute to Collaborate on the Discovery and Development of a Novel Drug to Treat Metabolic Diseases
Montreal (Canada) and Milan (Italy) – February 18, 2016 – Axxam SpA, a leading discovery company with expertise in target biology and a broad range of early phase discovery solutions and NEOMED Institute, a public-private organization dedicated to drug discovery and the development of therapeutics up to human proof of concept, announced today that they have entered into a strategic drug discovery partnership. The aim of the collaboration is to identify and develop novel small molecule agonists of FFA4 (also known as GPR120) linked to a range of metabolic and inflammatory diseases. Several preclinical studies and human genetics data support the development of a GPR120 agonist as a highly differentiated treatment of diabetes with potential to impact a number of parameters, including protection of the pancreatic β-cells.